• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Home >> Screening Panel >> DiscoveryProbe™ Endocrinology and Hormones-related Compounds Panel
Related Products
DiscoveryProbe™ Endocrinology and Hormones-related Compounds Panel

DiscoveryProbe™ Endocrinology and Hormones-related Compounds Panel

Catalog No. L1008
Size Price Stock Qty
5mg/well $1,990.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Click and Customize the Panel with your own choices of compounds/size/quantities/chemical forms etc.

HTS Facility Partners

Featured Products of the Panel

Catalog No. Product Name Summary Targets CAS Number Smiles
A2150 Andarine Selective androgen receptor agonist Endocrinology and Hormones|Androgen Receptor 401900-40-1 C(=O)NC1=CC=C(C=C1)OCC(C)(C(=O)NC2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)O
B1534 AZD1981 CRTh2 antagonist,potent and selective Endocrinology and Hormones|CRTH2 802904-66-1 CC1=C(C2=C(N1CC(=O)O)C=CC=C2NC(=O)C)SC3=CC=C(C=C3)Cl
A1428 Fulvestrant Estrogen receptor antagonist,high affinity Endocrinology and Hormones|Estrogen/progestogen Receptor 129453-61-8 CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
B1518 Erteberel (LY500307) Erβ agonist, potent and selective Endocrinology and Hormones|Estrogen/progestogen Receptor 533884-09-2 C1CC2C(C1)C3=C(C=CC(=C3)O)OC2C4=CC=C(C=C4)O
B3238 XCT790 ERRα agonist Endocrinology and Hormones|Estrogen/progestogen Receptor 725247-18-7 COC1=C(C=CC(=C1)C=C(C#N)C(=O)NC2=NN=C(S2)C(F)(F)F)OCC3=C(C=C(C=C3)C(F)(F)F)C(F)(F)F
A2986 ADL5859 HCl δ-opioid receptor agonist,selective Endocrinology and Hormones|Opioid Receptor 850173-95-4 CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=C2C(=CC=C4)O.Cl
A8456 JTC-801 KOR-3 (NOP) receptor antagonist, high affinity and selective Endocrinology and Hormones|Opioid Receptor 244218-51-7 CCC1=CC=C(C=C1)OCC2=CC=CC=C2C(=O)NC3=CC4=C(C=C3)N=C(C=C4N)C.Cl
A8019 Perindopril Erbumine Potent angiotensin-converting enzyme (ACE) inhibitor Endocrinology and Hormones|RAAS 107133-36-8 CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N
Download the Endocrinology and Hormones-related Compounds Panel - XLSX       Download the Endocrinology and Hormones-related Compounds Panel - SDF

Quality Control

Related Biological Data

MDV3100
KLK3 (top) and NKX3-1(bottom) expression which were the AR target genes in various resistant clones were analyzed by QPCR. All lines were pretreated with vehicle (−) or doxycycline (+) for 3 days before treatment with DMSO (left) or 10 μmol/L MDV3100 (right) for 24 hours in 10% FCS. TBP was used to normalize expression. Data represent mean ± SEM; n = 3. *, P < 0.05; **, P < 0.01 (Student t test). The F876L mutation is sufficient to induce genetic and phenotypic resistance to MDV3100.

Review (Georgia Regents University)

MDV3100
Comparison of different anti-androgen/AR compounds on TGF-β1/Smad3/MMP9 signaling in PCa cells. CWR22Rv1 cells treated with 10 μM CASO, 10 μM MDV, 10 μM ASC, 5 μM CTS, or vehicle for 3 days were harvested. The expressions of TGF-β1, p-Smad3, Smad3, MMP9, and GAPDH were analyzed by Western blot analysis. All of the experiments have been repeated twice independently. *, p< 0.05; **, p < 0.01; ***, p < 0.001. Error bars, S.D. Casodex and MDV3100 enhanced TGF-beta, MMP9 expression in CWR22Rv1 cells. whereas ASC-J9 and CTS treatment did not.

Review (University of Glasgow )

MDV3100
Chronic exposure to ENZA resulted in autophagy. To mimic resistant to ENZA, C4-2B cells were subjected to 20 μM ENZA over a period of 3 months and selected for a sub-population of resistance cells (C4-2B+R). Upper panel showed acridine orange staining of autophagosome acidic vesicles as a marker for autophagy. Lower panel showed LC3-I/II protein expression in parental cells (control) and under chronic ENZA exposure-treated vehicle control, chloroquine (CQ) or CMI. β -Actin was used as the loading control.

Signaling Pathway

Androgen Receptor Compare Products
Estrogen/progestogen Receptor Compare Products
Opioid Receptor Compare Products

Advantages

  • Available in stock with overnight delivery and free shipping over $500
  • Cost-effective and competitive price to save your findings
  • Potent, selective and cell-permeable in inhibiting or activating target molecules
  • Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.)
  • Detailed files describing potency, selectivity and applications etc.
  • Supported by published data from top peer-reviewed journals
  • Guaranteed high quality with NMR and HPLC validation

Storage and Shipping Information

Solubility Soluble in DMSO Storage Desiccate at -20°C
Packaging 96 well plate Form Powder
General tips For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

A wide range of well-characterized bioactive molecules that covers various targets related to endocrinology and hormones, including androgen receptor, estrogen/progestogen receptor and RAAS etc. Facilitate your research towards the insights of diabetes, thyroid disorders and cancer etc. Applicable in cellular assays, animal models and drug screenings etc.

References

1. Kaarbø M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 2007 Dec;29(12):1227-38.
Abstract
The androgen receptor (AR) is required for prostate cancer growth in all stages. This review focuses on AR function and AR-target genes and summarizes the major signaling pathways implicated in prostate cancer progression, their crosstalk with each other and with AR signaling. This complex network of interactions is providing a deeper insight into prostate carcinogenesis and may form the basis for novel diagnostic and therapeutic strategies.